- Home
- PBA vs ONC Comparison
PBA vs ONC Comparison
Compare PBA & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBA | ONC |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | Canada | Switzerland |
| Employees | 2974 | 12000 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 31.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBA | ONC |
|---|---|---|
| Price | $48.99 | $293.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $60.00 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 784.1K | 193.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.45 | $723.76 |
| Revenue Next Year | $9.15 | $15.04 |
| P/E Ratio | ★ $21.43 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.45 | $228.93 |
| 52 Week High | $48.62 | $385.22 |
Technical Indicators
Market Signals| Indicator | PBA | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 74.64 | 41.84 |
| Support Level | $42.24 | $275.79 |
| Resistance Level | N/A | $314.18 |
| Average True Range (ATR) | 0.90 | 8.16 |
| MACD | 0.38 | -0.22 |
| Stochastic Oscillator | 98.73 | 15.90 |
Price Performance
Historical ComparisonAbout PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports. It also has a joint venture through the Cedar LNG export terminal.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.